|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: DNAJC8 |
Gene summary for DNAJC8 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | DNAJC8 | Gene ID | 22826 |
| Gene name | DnaJ heat shock protein family (Hsp40) member C8 | |
| Gene Alias | HSPC331 | |
| Cytomap | 1p35.3 | |
| Gene Type | protein-coding | GO ID | GO:0005575 | UniProtAcc | O75937 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 22826 | DNAJC8 | HTA11_2487_2000001011 | Human | Colorectum | SER | 3.53e-04 | 2.98e-01 | -0.1808 |
| 22826 | DNAJC8 | HTA11_1938_2000001011 | Human | Colorectum | AD | 7.58e-06 | 4.27e-01 | -0.0811 |
| 22826 | DNAJC8 | HTA11_78_2000001011 | Human | Colorectum | AD | 8.78e-04 | 3.32e-01 | -0.1088 |
| 22826 | DNAJC8 | HTA11_347_2000001011 | Human | Colorectum | AD | 1.91e-11 | 4.10e-01 | -0.1954 |
| 22826 | DNAJC8 | HTA11_83_2000001011 | Human | Colorectum | SER | 1.38e-05 | 3.05e-01 | -0.1526 |
| 22826 | DNAJC8 | HTA11_1391_2000001011 | Human | Colorectum | AD | 4.86e-11 | 5.39e-01 | -0.059 |
| 22826 | DNAJC8 | HTA11_99999970781_79442 | Human | Colorectum | MSS | 3.95e-02 | 3.10e-01 | 0.294 |
| 22826 | DNAJC8 | HTA11_99999965104_69814 | Human | Colorectum | MSS | 1.00e-05 | 4.43e-01 | 0.281 |
| 22826 | DNAJC8 | HTA11_99999971662_82457 | Human | Colorectum | MSS | 3.10e-12 | 4.74e-01 | 0.3859 |
| 22826 | DNAJC8 | AEH-subject1 | Human | Endometrium | AEH | 1.06e-17 | -4.10e-01 | -0.3059 |
| 22826 | DNAJC8 | AEH-subject2 | Human | Endometrium | AEH | 4.15e-17 | -4.43e-01 | -0.2525 |
| 22826 | DNAJC8 | AEH-subject3 | Human | Endometrium | AEH | 5.58e-16 | -4.07e-01 | -0.2576 |
| 22826 | DNAJC8 | AEH-subject4 | Human | Endometrium | AEH | 3.21e-08 | -3.20e-01 | -0.2657 |
| 22826 | DNAJC8 | AEH-subject5 | Human | Endometrium | AEH | 5.26e-18 | -4.32e-01 | -0.2953 |
| 22826 | DNAJC8 | EEC-subject1 | Human | Endometrium | EEC | 2.01e-21 | -4.76e-01 | -0.2682 |
| 22826 | DNAJC8 | EEC-subject2 | Human | Endometrium | EEC | 1.81e-17 | -4.37e-01 | -0.2607 |
| 22826 | DNAJC8 | EEC-subject3 | Human | Endometrium | EEC | 4.05e-40 | -4.56e-01 | -0.2525 |
| 22826 | DNAJC8 | EEC-subject4 | Human | Endometrium | EEC | 1.36e-19 | -3.66e-01 | -0.2571 |
| 22826 | DNAJC8 | EEC-subject5 | Human | Endometrium | EEC | 1.21e-03 | -2.21e-01 | -0.249 |
| 22826 | DNAJC8 | GSM5276934 | Human | Endometrium | EEC | 2.04e-04 | 8.65e-02 | -0.0913 |
| Page: 1 2 3 4 5 6 7 8 9 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Endometrium |  | AEH: Atypical endometrial hyperplasia |
| EEC: Endometrioid Cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| DNAJC8 | insertion | In_Frame_Ins | novel | c.23_24insAGTTTTGCTCTTGTTGCCCAGGCCTGGAGTGCA | p.Gly8_Thr9insValLeuLeuLeuLeuProArgProGlyValGln | p.G8_T9insVLLLLPRPGVQ | O75937 | protein_coding | TCGA-B6-A0I6-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | PD | ||
| DNAJC8 | SNV | Missense_Mutation | c.126N>C | p.Gln42His | p.Q42H | O75937 | protein_coding | deleterious(0.02) | benign(0.183) | TCGA-C5-A1BK-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
| DNAJC8 | SNV | Missense_Mutation | c.583N>A | p.Glu195Lys | p.E195K | O75937 | protein_coding | tolerated(0.05) | possibly_damaging(0.614) | TCGA-C5-A1BQ-01 | Cervix | cervical & endocervical cancer | Female | >=65 | III/IV | Chemotherapy | cisplatin | CR | |
| DNAJC8 | SNV | Missense_Mutation | c.583N>A | p.Glu195Lys | p.E195K | O75937 | protein_coding | tolerated(0.05) | possibly_damaging(0.614) | TCGA-C5-A3HL-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Unknown | Unknown | SD | |
| DNAJC8 | SNV | Missense_Mutation | novel | c.76N>A | p.Glu26Lys | p.E26K | O75937 | protein_coding | deleterious(0) | probably_damaging(0.983) | TCGA-MA-AA41-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
| DNAJC8 | insertion | In_Frame_Ins | novel | c.655_656insTAT | p.Arg219delinsLeuCys | p.R219delinsLC | O75937 | protein_coding | TCGA-DS-A1OC-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | gemcitabine | SD | ||
| DNAJC8 | SNV | Missense_Mutation | c.643N>C | p.Ser215Arg | p.S215R | O75937 | protein_coding | deleterious(0) | possibly_damaging(0.526) | TCGA-AA-A010-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Chemotherapy | folinic | CR | |
| DNAJC8 | SNV | Missense_Mutation | novel | c.263N>C | p.Lys88Thr | p.K88T | O75937 | protein_coding | deleterious(0.02) | probably_damaging(0.987) | TCGA-CA-6717-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Chemotherapy | oxaliplatin | CR |
| DNAJC8 | SNV | Missense_Mutation | c.20G>A | p.Ser7Asn | p.S7N | O75937 | protein_coding | tolerated(0.17) | benign(0.015) | TCGA-G4-6304-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Chemotherapy | fluorouracil | PD | |
| DNAJC8 | SNV | Missense_Mutation | c.228N>C | p.Arg76Ser | p.R76S | O75937 | protein_coding | deleterious(0.01) | benign(0.324) | TCGA-NH-A5IV-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |